Labnovation Technologies, Inc.

Labnovation Technologies, Inc. was founded on May 24, 2001, with a registered capital of RMB 10.01 million, and is located in Guangming District, Shenzhen. Since 2014, it has been recognized as a National High-Tech Enterprise for 12 consecutive years.

The company specializes in the R&D, manufacturing, sales, and service of in vitro diagnostic (IVD) instruments and reagents, and is the only company with dual technology platforms for glycated hemoglobin (HbA1c) analyzers. Its main products include HbA1c analyzers, glucose/lactate analyzers, quantitative immunoassay analyzers, reagents for hematology analyzers, rapid diagnostic reagents, etc.

The company places great emphasis on establishing and improving its quality management system. It was among the first in the industry to obtain TÜV certification for the ISO 9001:2008 and ISO 13485:2003+AC:2009 quality management systems, and has also obtained EU CE certification, U.S. FDA registration, the U.S. NGSP certificate, and the IFCC certificate from the International Federation of Clinical Chemistry and Laboratory Medicine.

It has been granted 9 invention patents, 23 utility model patents, 6 design patents, 12 software copyrights, 8 domestic trademarks, and 6 international trademarks.

In addition to normal functional conditions required for office, research, and production—such as ventilation, air conditioning, fire protection, water supply and drainage, dual-circuit power supply, communications, and IT infrastructure—the company is equipped with professional equipment and facilities for IVD product development, including professional R&D laboratories, waveform generators, digital oscilloscopes, constant-temperature soldering stations, desoldering stations, inductance-capacitance meters, numerically controlled DC linear regulated power supplies, as well as regulatory-compliant production workshops, cleanrooms, professional production workbenches, safety compliance testers, and constant-temperature-and-humidity aging chambers.

Each year, the company invests more than 16% of its sales revenue in product R&D, hardware construction, and upgrades. In response to customer needs and market development, it ensures the timely launch of new products and the upgrading and replacement of existing products. With superior quality and outstanding cost-effectiveness, the market share of its products in both domestic and international markets has increased year by year. As the first company in China to develop five-part differential hematology reagents, Labnovation’s product quality leads comparable products on the market. In addition to covering the domestic market, its products have successfully entered markets in more than 60 countries across Europe, the Americas, Asia, the Middle East, and Africa, and have been widely praised by users at home and abroad. In 2018, it ranked among the top 15 medical device exporters in Shenzhen.

To help more customers learn about Labnovation, the company participates every year in renowned professional medical exhibitions at home and abroad, including CMEF, Medica, AACC, and others. To date, its brand has become known to an increasing number of customers, and it has won more and more long-term domestic and international partners through quality and integrity.

Customer-oriented, based on high-quality products, and premised on fast and considerate service, the company will adhere to the spirit of “Focus, Pragmatism, Innovation, and Win-Win,” continue as always to provide global clinical laboratories with efficient, rapid, accurate, and cost-effective IVD products and services, and strive to become a global leader in IVD products.